SCH 412348

Drug Profile

SCH 412348

Alternative Names: SCH-412348; SCH-58261

Latest Information Update: 30 Oct 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Schering-Plough
  • Class Antiparkinsonians
  • Mechanism of Action Adenosine A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 30 Oct 2009 Discontinued - Phase-II for Parkinson's disease in USA (PO)
  • 07 Nov 2007 Pharmacodynamics data from a preclinical study presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007)
  • 28 Feb 2007 Phase-II clinical trials in Parkinson's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top